Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia

I. Bitter, Jeffrey A. Lieberman, Florence Gaudoux, Pierre Sokoloff, Mélanie Groc, Rajeev Chavda, Cécile Delsol, Laurence Barthe, Valérie Brunner, Carine Fabre, Marine Fagard, Agnès Montagne, Françoise Tonner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Change from baseline to Day 43 of the Positive and Negative Syndrome Scale (PANSS) total score was the primary outcome. The data from 134 randomized patients (67 per group) were analyzed (efficacy/safety). Using analysis of covariance (ANCOVA) after last observation carried forward (LOCF) imputation (primary analysis), the PANSS total score reduction was statistically significantly greater for F17464 than placebo treated subjects at endpoint (p = 0.014); using ANCOVA with Multiple Imputation (MI) method, the between-group difference was in favor of F17464 but did not reach statistical significance. Differences in PANSS positive and general psychopathology subscale score, Marder positive factor score, PANSS response, and PANSS resolution criteria were also statistically significant in favor of F17464 (p values < 0.05) using the LOCF method, with similar results as for the primary analysis using the MI method. Treatment-related adverse events (AEs) were reported in 49.3% and 46.3% of patients on F17464 and placebo, respectively. The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile.

Original languageEnglish
JournalNeuropsychopharmacology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Schizophrenia
Placebos
Safety
Observation
Basal Ganglia Diseases
Therapeutics
Psychomotor Agitation
Sleep Initiation and Maintenance Disorders
Psychopathology
Weight Gain
Triglycerides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia . / Bitter, I.; Lieberman, Jeffrey A.; Gaudoux, Florence; Sokoloff, Pierre; Groc, Mélanie; Chavda, Rajeev; Delsol, Cécile; Barthe, Laurence; Brunner, Valérie; Fabre, Carine; Fagard, Marine; Montagne, Agnès; Tonner, Françoise.

In: Neuropsychopharmacology, 01.01.2019.

Research output: Contribution to journalArticle

Bitter, I, Lieberman, JA, Gaudoux, F, Sokoloff, P, Groc, M, Chavda, R, Delsol, C, Barthe, L, Brunner, V, Fabre, C, Fagard, M, Montagne, A & Tonner, F 2019, ' Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia ', Neuropsychopharmacology. https://doi.org/10.1038/s41386-019-0355-2
Bitter, I. ; Lieberman, Jeffrey A. ; Gaudoux, Florence ; Sokoloff, Pierre ; Groc, Mélanie ; Chavda, Rajeev ; Delsol, Cécile ; Barthe, Laurence ; Brunner, Valérie ; Fabre, Carine ; Fagard, Marine ; Montagne, Agnès ; Tonner, Françoise. / Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia In: Neuropsychopharmacology. 2019.
@article{f83e0f4364cf4502a31f8b4f1148e0a6,
title = "Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia",
abstract = "F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Change from baseline to Day 43 of the Positive and Negative Syndrome Scale (PANSS) total score was the primary outcome. The data from 134 randomized patients (67 per group) were analyzed (efficacy/safety). Using analysis of covariance (ANCOVA) after last observation carried forward (LOCF) imputation (primary analysis), the PANSS total score reduction was statistically significantly greater for F17464 than placebo treated subjects at endpoint (p = 0.014); using ANCOVA with Multiple Imputation (MI) method, the between-group difference was in favor of F17464 but did not reach statistical significance. Differences in PANSS positive and general psychopathology subscale score, Marder positive factor score, PANSS response, and PANSS resolution criteria were also statistically significant in favor of F17464 (p values < 0.05) using the LOCF method, with similar results as for the primary analysis using the MI method. Treatment-related adverse events (AEs) were reported in 49.3{\%} and 46.3{\%} of patients on F17464 and placebo, respectively. The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile.",
author = "I. Bitter and Lieberman, {Jeffrey A.} and Florence Gaudoux and Pierre Sokoloff and M{\'e}lanie Groc and Rajeev Chavda and C{\'e}cile Delsol and Laurence Barthe and Val{\'e}rie Brunner and Carine Fabre and Marine Fagard and Agn{\`e}s Montagne and Fran{\cc}oise Tonner",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41386-019-0355-2",
language = "English",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Randomized, double-blind, placebo-controlled study of F17464, a preferential D 3 antagonist, in the treatment of acute exacerbation of schizophrenia

AU - Bitter, I.

AU - Lieberman, Jeffrey A.

AU - Gaudoux, Florence

AU - Sokoloff, Pierre

AU - Groc, Mélanie

AU - Chavda, Rajeev

AU - Delsol, Cécile

AU - Barthe, Laurence

AU - Brunner, Valérie

AU - Fabre, Carine

AU - Fagard, Marine

AU - Montagne, Agnès

AU - Tonner, Françoise

PY - 2019/1/1

Y1 - 2019/1/1

N2 - F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Change from baseline to Day 43 of the Positive and Negative Syndrome Scale (PANSS) total score was the primary outcome. The data from 134 randomized patients (67 per group) were analyzed (efficacy/safety). Using analysis of covariance (ANCOVA) after last observation carried forward (LOCF) imputation (primary analysis), the PANSS total score reduction was statistically significantly greater for F17464 than placebo treated subjects at endpoint (p = 0.014); using ANCOVA with Multiple Imputation (MI) method, the between-group difference was in favor of F17464 but did not reach statistical significance. Differences in PANSS positive and general psychopathology subscale score, Marder positive factor score, PANSS response, and PANSS resolution criteria were also statistically significant in favor of F17464 (p values < 0.05) using the LOCF method, with similar results as for the primary analysis using the MI method. Treatment-related adverse events (AEs) were reported in 49.3% and 46.3% of patients on F17464 and placebo, respectively. The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile.

AB - F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Change from baseline to Day 43 of the Positive and Negative Syndrome Scale (PANSS) total score was the primary outcome. The data from 134 randomized patients (67 per group) were analyzed (efficacy/safety). Using analysis of covariance (ANCOVA) after last observation carried forward (LOCF) imputation (primary analysis), the PANSS total score reduction was statistically significantly greater for F17464 than placebo treated subjects at endpoint (p = 0.014); using ANCOVA with Multiple Imputation (MI) method, the between-group difference was in favor of F17464 but did not reach statistical significance. Differences in PANSS positive and general psychopathology subscale score, Marder positive factor score, PANSS response, and PANSS resolution criteria were also statistically significant in favor of F17464 (p values < 0.05) using the LOCF method, with similar results as for the primary analysis using the MI method. Treatment-related adverse events (AEs) were reported in 49.3% and 46.3% of patients on F17464 and placebo, respectively. The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile.

UR - http://www.scopus.com/inward/record.url?scp=85063464003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063464003&partnerID=8YFLogxK

U2 - 10.1038/s41386-019-0355-2

DO - 10.1038/s41386-019-0355-2

M3 - Article

AN - SCOPUS:85063464003

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -